On September 21, 2022 Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, reported a poster presentation at the 2022 International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper) (CICON) in New York City, NY, from September 28 – October 1, 2022 (Press release, Imvax, SEP 21, 2022, View Source;utm_medium=rss&utm_campaign=imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference [SID1234621350]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the meeting, Imvax will present preclinical data that further elucidate the foundational anti-tumor immunological mechanisms of its platform and provide additional evidence of activity in an endometrial cancer model.

The details of the poster presentation are:

Title: Autologous tumor cell immunotherapeutic platform, with evidence of clinical activity in glioblastoma, induces in vitro immune responses in both glioblastoma and endometrial cancer